NO981592L - Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten - Google Patents

Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Info

Publication number
NO981592L
NO981592L NO981592A NO981592A NO981592L NO 981592 L NO981592 L NO 981592L NO 981592 A NO981592 A NO 981592A NO 981592 A NO981592 A NO 981592A NO 981592 L NO981592 L NO 981592L
Authority
NO
Norway
Prior art keywords
rar
gamma
apoptosis rate
specific agonist
agonist ligand
Prior art date
Application number
NO981592A
Other languages
English (en)
Norwegian (no)
Other versions
NO981592D0 (no
Inventor
Laszlo Fesus
Zsuzsa Szondy
Uwe Reichert
Original Assignee
Cird Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cird Galderma filed Critical Cird Galderma
Publication of NO981592D0 publication Critical patent/NO981592D0/no
Publication of NO981592L publication Critical patent/NO981592L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO981592A 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten NO981592L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9512179A FR2739557B1 (fr) 1995-10-09 1995-10-09 Utilisation d'un ligand agoniste specifique rar-gamma
PCT/FR1996/001568 WO1997013505A2 (fr) 1995-10-09 1996-10-08 UTILISATION D'UN LIGAND AGONISTE SPECIFIQUE RAR-η POUR AUGMENTER LE TAUX D'APOPTOSE

Publications (2)

Publication Number Publication Date
NO981592D0 NO981592D0 (no) 1998-04-07
NO981592L true NO981592L (no) 1998-06-09

Family

ID=9483613

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981592A NO981592L (no) 1995-10-09 1998-04-07 Anvendelse av <gamma>-RAR-spesifikk agonistligand for Õ °ke apoptosisraten

Country Status (16)

Country Link
US (4) US6593359B1 (pt)
EP (1) EP0854710A2 (pt)
JP (1) JP3135266B2 (pt)
KR (1) KR19990064139A (pt)
CN (1) CN1121857C (pt)
AU (1) AU705993B2 (pt)
BR (1) BR9610967A (pt)
CA (1) CA2231561A1 (pt)
FR (1) FR2739557B1 (pt)
HU (1) HUP9900453A3 (pt)
NO (1) NO981592L (pt)
NZ (1) NZ319646A (pt)
PL (1) PL185826B1 (pt)
RU (1) RU2188037C2 (pt)
TR (1) TR199800645T1 (pt)
WO (1) WO1997013505A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20030053991A1 (en) * 2000-10-04 2003-03-20 Kingsman Alan John Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
FR2757852B1 (fr) 1996-12-31 1999-02-19 Cird Galderma Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
WO1999024024A2 (en) 1997-11-12 1999-05-20 F. Hoffmann-La Roche Ag Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6949528B1 (en) * 1998-03-18 2005-09-27 Goddard John G Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
AU2003294757A1 (en) * 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
US20050202055A1 (en) * 2004-03-11 2005-09-15 Koichi Shudo, Tokyo, Japan Anti-wrinkle agent
CN1933802B (zh) * 2004-03-26 2011-07-06 帝斯曼知识产权资产管理有限公司 包含hdac抑制剂和类维生素a的组合的组合物
US7850683B2 (en) * 2005-05-20 2010-12-14 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7713266B2 (en) 2005-05-20 2010-05-11 Myoscience, Inc. Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US9254162B2 (en) 2006-12-21 2016-02-09 Myoscience, Inc. Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en) * 2007-02-16 2013-04-02 Myoscience, Inc. Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US8298216B2 (en) 2007-11-14 2012-10-30 Myoscience, Inc. Pain management using cryogenic remodeling
AU2009330012A1 (en) 2008-12-22 2011-07-21 Myoscience, Inc. Integrated cryosurgical system with refrigerant and electrical power source
MX361414B (es) 2010-09-01 2018-12-05 Univ Jefferson Composición y método para reparación y regeneración muscular.
ES2759584T3 (es) * 2011-06-24 2020-05-11 Gri Bio Inc Prevención y tratamiento de afecciones inflamatorias
EP2802280B1 (en) 2012-01-13 2016-11-30 Myoscience, Inc. Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
EP2802279B1 (en) 2012-01-13 2017-08-16 Myoscience, Inc. Cryogenic needle with freeze zone regulation
WO2013106860A1 (en) 2012-01-13 2013-07-18 Myoscience, Inc. Cryogenic probe filtration system
US9017318B2 (en) 2012-01-20 2015-04-28 Myoscience, Inc. Cryogenic probe system and method
CN105208954B (zh) 2013-03-15 2019-06-04 肌肉科技股份有限公司 低温钝性解剖方法和设备
US9610112B2 (en) 2013-03-15 2017-04-04 Myoscience, Inc. Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
US9295512B2 (en) 2013-03-15 2016-03-29 Myoscience, Inc. Methods and devices for pain management
WO2014146122A1 (en) 2013-03-15 2014-09-18 Myoscience, Inc. Methods and systems for treatment of occipital neuralgia
US10130409B2 (en) 2013-11-05 2018-11-20 Myoscience, Inc. Secure cryosurgical treatment system
EP3957304A1 (en) 2015-11-25 2022-02-23 IO Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
US11311327B2 (en) 2016-05-13 2022-04-26 Pacira Cryotech, Inc. Methods and systems for locating and treating nerves with cold therapy
KR20190017950A (ko) 2016-06-10 2019-02-20 아이오 테라퓨틱스, 인크. 암 면역요법을 위한 수용체 선택적 레티노이드 및 렉시노이드 화합물 및 면역 조절제
CA3069672A1 (en) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3709918A4 (en) 2017-11-15 2021-08-11 Pacira CryoTech, Inc. INTEGRATED COLD THERAPY AND ELECTRIC STIMULATION SYSTEMS FOR LOCALIZATION AND TREATMENT OF NERVE AND RELATED PROCEDURES
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786391A (en) * 1995-01-11 1998-07-28 Cornell Research Foundation, Inc. Regulating gene expression using retinoids with Ch2 OH or related groups at the side chain terminal position
WO1997003682A1 (en) * 1995-07-17 1997-02-06 Centre International De Recherches Dermatologiques C.I.R.D. Galderma Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Also Published As

Publication number Publication date
HUP9900453A3 (en) 1999-11-29
US6506796B1 (en) 2003-01-14
AU7220996A (en) 1997-04-30
HUP9900453A2 (hu) 1999-05-28
NO981592D0 (no) 1998-04-07
US6686386B1 (en) 2004-02-03
US6593359B1 (en) 2003-07-15
FR2739557A1 (fr) 1997-04-11
KR19990064139A (ko) 1999-07-26
PL326077A1 (en) 1998-08-17
NZ319646A (en) 2000-08-25
BR9610967A (pt) 1999-03-02
JP3135266B2 (ja) 2001-02-13
WO1997013505A2 (fr) 1997-04-17
AU705993B2 (en) 1999-06-03
CA2231561A1 (fr) 1997-04-17
WO1997013505A3 (fr) 1997-05-29
RU2188037C2 (ru) 2002-08-27
PL185826B1 (pl) 2003-08-29
JPH11501661A (ja) 1999-02-09
TR199800645T1 (xx) 1998-06-22
CN1121857C (zh) 2003-09-24
US20010018456A1 (en) 2001-08-30
EP0854710A2 (fr) 1998-07-29
FR2739557B1 (fr) 1997-11-14
CN1203528A (zh) 1998-12-30

Similar Documents

Publication Publication Date Title
NO981592L (no) Anvendelse av &lt;gamma&gt;-RAR-spesifikk agonistligand for Õ °ke apoptosisraten
NO981038D0 (no) Glykolbasert borevæske
NO974511D0 (no) Deteksjon av mulig ulovlig kommunikasjonsbruk
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
NO992585D0 (no) MÕling av gasstr°mningsrate
BR9709051A (pt) Derivados de indazol substituidos e compostos relacionados
NO985242D0 (no) Tetrahydroisokinolin-derivater som modulatorer for dopamin D3-reseptorer
HUP9900037A3 (en) Use of rar-gamma antagonist or alfa-rar-alfa agonist ligands to prepare pharmaceutical compositions for reducing apoptosis
FI930636A (fi) Foerfarande foer framstaellning av en flerstegspolymer
NO982462D0 (no) MÕling av fyllingsgrad
NO921402D0 (no) Tankagitator for tidlig hydratisering av konsentrert, flytende, geledannende middel
FI934151A0 (fi) Foerfarande foer framstaellning av en baerarkatalysator foer polymerisationav a-olefiner
DE69819903D1 (de) Bizyklische verbindungen als liganden der 5-ht1 rezeptoren
NO983298L (no) System for Õ begrense bruk av et mÕleapparat
DE69409631D1 (de) Flüssigkeitsdetektor
FI930800A0 (fi) Foerfarande foer avlaegsning av laett oxiderbara organiska foereningar fraongasstroemmar
DE69309191D1 (de) Thermistor-Flüssigkeitsdetektor
FI931482A0 (fi) Foerfarande foer framstaellning av en ziegler-natta-katalysator
ID18290A (id) Detektor batas cairan
FI963532A (fi) Kinoliini-3-karboksamidiyhdisteiden uusi käyttö
NO20006444D0 (no) Referanseforbindelse for anvendelse i ananlyser av levosimendanporsjoner
NO970126D0 (no) Anvendelse av benzaldhyder for markering av hydrokarboner
NO940190D0 (no) Anvendelse av x-ketoglutarat
KR970701546A (ko) 퀴놀린-3-카르복사미드 화합물의 새로운 용도(new use of quinoline-3-carboxamide compounds)
FI932409A0 (fi) Samtidig generering och maetning av en friktionselektrisk laddning pao en yta

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application